Neuromuscular and Systemic Presentations in Adults: Diagnoses beyond MERRF and MELAS

Neurotherapeutics

Volumn 10, Issue 2, 2013, Pages 227-242

  Cohen, Bruce H ^a  

^a AKRON CHILDREN'S HOSPITAL   (United States)

Author keywords

Clinical evaluation; Mitochondria; Mitochondrial genetics; mtDNA; Muscle enzymology; Myopathy

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE KINASE; CYTOCHROME C; MITOCHONDRIAL DNA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PREALBUMIN; TRANSFER RNA;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CEREBROSPINAL FLUID ANALYSIS; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; CORRELATION ANALYSIS; DIABETES MELLITUS; EHLERS DANLOS SYNDROME; ELECTROMYOGRAPHY; HUMAN; HYPERLIPIDEMIA; HYPERTHYROIDISM; HYPOTHYROIDISM; MELAS SYNDROME; MERRF SYNDROME; MITOCHONDRIAL DNA DEPLETION SYNDROME; MITOCHONDRIAL ENERGY TRANSFER; MUSCLE WEAKNESS; MUTATIONAL ANALYSIS; MYASTHENIA GRAVIS; MYOTONIC DYSTROPHY; NARP SYNDROME; NERVE CONDUCTION; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPTIC NERVE ATROPHY; OXIDATION REDUCTION REACTION; OXIDATIVE PHOSPHORYLATION; POINT MUTATION; PRESCRIPTION; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84876169657     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0188-3     Document Type: Review

References (91)

1. DiMauro S, Bonilla E. Mitochondrial encephalomyopathies. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL (eds) The molecular and genetic basis of neurological disease. Butterworth-Heinemann, Boston, MA; 1997: pp. 201-235.
2. Shoffner JM, Wallace DC. Oxidative phosphorylation diseases. In: Scriver CR, Beaudet AL, Sly WS, et al. (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York; 1995: pp. 1535-1610.
3. DiMauro S, Schon EA,. The mitochondrial respiratory chain and its disorders. In: DiMauro S, Hirano M, Schon EA (eds) Mitochondrial medicine. Informa Healthcare, Boca Raton, FL; 2006: pp. 7-26.
4. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annu Rev Pathol 2010; 5: 297-348.
5. Cooper JM, Clark JB. The structural organization of the mitochondrial respiratory chain. In: Schapira AHV, DiMauro S (eds) Mitochondrial disorders in neurology. Butterworth-Heinemann, Oxford; 1994; pp. 1-30.
6. Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell 2008; 134: 112-123.
7. Haas RH, Parikh S, Falk MH, et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab 2008; 94: 16-37.
8. Bernier FP, Boneh A, Dennett X, et al. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002; 59: 1406-1411.
9. Wolf NI, Smeitink JA. Mitochondrial disorders: a proposal for consensus diagnostic criteria in infants and children. Neurology 2002; 59: 1402-1405.
10. Friedman SD, Shaw DW, Ishak G, Gropman AL, Saneto RP. The use of neuroimaging in the diagnosis of mitochondrial disease. Dev Disabil Res Rev 2010; 16: 129-135.
11. Hammans SR, Morgan-Hughes JA. Mitochondrial myopathies: clinical features, investigation, treatment and genetic counseling. In: Schapira AHV, DiMauro S (eds) Mitochondrial disorders in neurology. Butterworth-Heinemann, Oxford; 1994: pp. 1-30.
12. Chinnery PF. Mitochondrial DNA polymerase-gamma and human disease. Hum Mol Genet 2006; 15: R244-252.
13. Hinson JT, Fantin VR, Schönberger J, et al. Missense mutations in the BCS1L gene as a cause of the Björnstad syndrome. N Engl J Med 2007; 356: 809-819.
14. Schon EA. Mitochondrial DNA and the genetics of mitochondrial disease. In: Schapira AHV, DiMauro S (eds) Mitochondrial disorders in neurology. Butterworth-Heinemann, Oxford; 1994; pp. 31-48.
15. Fan W, Waymire KG, Narula N, et al. A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations. Science 2008; 319: 958-962.
16. Stewart JD, Horvath R, Baruffini E, et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010; 52: 1791-1796.
17. Wallace DC. Mitochondrial DNA mutations and bioenergetic defects in aging and degenerative diseases. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL (eds). The molecular and genetic basis of neurologic disease. Butterworth-Heinemann, Boston, MA; 1997: pp. 237-269.
18. Melov S, Shoffner JM, Kaufman A, Wallace DC. Marked increase in the number and variety of mitochondrial DNA rearrangements in aging human skeletal muscle. Nucleic Acids Res 1995; 23: 4122-4126.
19. Andreu AL, Hanna MG, Reichmann H, et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med 1999; 341: 1037-1044.
20. Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993; 4: 289-294.
21. Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat Res 1992; 275: 169-180.
22. Bird TD. Myotonic dystrophy type 1. In: Pagon RA, Bird TD, Dolan CR, et al. (eds) GeneReviews™. Available via http://www. ncbi. nlm. nih. gov/books/NBK1165/. Accessed 20 Mar 2013.
23. Brais B, Rouleau GA. Oculopharyngeal muscular dystrophy. In: Pagon RA, Bird TD, Dolan CR, et al. (eds) GeneReviews™. Available via http://www. ncbi. nlm. nih. gov/books/NBK1126/. Accessed 20 Mar 2013.
24. Gerrits KH, Voermans NC, de Haan A, van Engelen BG. Neuromuscular properties of the thigh muscles in patients with Ehlers-Danlos syndrome. Muscle Nerve 2013; 47: 96-104.
25. Celletti C, Galli M, Cimolin V, Castori M, Albertini G, Camerota F. Relationship between fatigue and gait abnormality in joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type. Res Dev Disabil 2012; 33: 1914-1918.
26. Voermans NC, van Alfen N, Pillen S, Lammens M, Schalkwijk J, Zwarts MJ, et al. Neuromuscular involvement in various types of Ehlers-Danlos syndrome. Ann Neurol 2009; 65: 687-697.
27. Rosenberg H, Sambuughin N, Riazi S, et al. Malignant hyperthermia susceptibility. In: Pagon RA, Bird TD, Dolan CR, et al. (eds) GeneReviews™. Available via http://www. ncbi. nlm. nih. gov/books/NBK1146/. Accessed 20 Mar 2013.
28. Barbeau A. The syndrome of hereditary late-onset ptosis and dysphagia in French Canada. In: Kuhn E (ed.) Symposium über progressive muskeldystrophie. Springer-Verlag, Berlin; 1996: pp. 102-109.
29. Quinlivan R, Jungbluth H. Myopathic causes of exercise intolerance with rhabdomyolysis. Dev Med Child Neurol 2012; 54: 886-891.
30. Michot C, Hubert L, Romero NB, et al. Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia. J Inherit Metab Dis 2012; 35: 1119-1128.
31. Pavlakis SG, Phillips PC, DiMauro S, DeVivo DC, Rowland LP. Mitochondrial myopathy, encephalomyopathy, lactic acidosis and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 1984; 16: 481-488.
32. Goto Y, Nonaka I, Horai S. A mutation in the tRNALeu(URR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990; 348: 653.
33. Bardosi A, Creutzfeldt W, DiMauro S, et al. Myo-, neuro-, gastrointestinal encephalomyopathy (MNGIE syndrome) due to partial deficiency of cytochrome c oxidase: a new mitochondrial multisystem disorder. Acta Neuropathol (Berl) 1987; 74:(3)248-258.
34. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999; 283: 689-692.
35. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ, Chen J. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol 2011; 95: 373-395.
36. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol 2004; 555: 1-13.
37. Lietman PS. Mitochondrial protein synthesis: inhibition by emetine hydrochloride. Mol Pharmacol 1971; 7: 122-128.
38. Hirano M, Kaufmann P, De Vivo D, Tanji K. Mitochondrial neurology I: encephlopathies. In: DiMauro S, Hirano M, Schon EA (eds) Mitochondrial medicine. Informa Healthcare, Boca Raton, FL; 2006: pp. 27-44.
39. Goodfellow JA, Dani K, Stewart W, Santosh C, McLean J, Mulhern S, Razvi S. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: an important cause of stroke in young people. Postgrad Med J 2012; 88: 326-334.
40. Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem 2006; 17: 571-588.
41. Wong LJ. Mitochondrial syndromes with leukoencephalopathies. Semin Neurol 2012; 32: 55-61.
42. Bindoff LA, Engelsen BA. Mitochondrial diseases and epilepsy. Epilepsia 2012; 53(Suppl. 4): 92-97.
43. Cohen BH, Naviaux RK. The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. Methods 2010; 51: 364-373.
44. Cohen BH, Chinnery PF, Copeland WC. POLG-related disorders. In: Pagon RA, Bird TD, Dolan CR, et al. (eds) GeneReviews™. Available via http://www. ncbi. nlm. nih. gov/books/NBK26471/. Accessed XXX.
45. Saneto RP, Lee I-C, Koenig MK, Bao X, Weng SW, Naviaux RK, Wong L-J. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 2010; 19: 140-146.
46. Huang CC, Chu CC, Pang CY, Wei YH. Tissue mosaicism in the skeletal muscle and sural nerve biopsies in the MELAS syndrome. Acta Neurol Scand 1999; 99: 125-129.
47. Peyronnard JM, Charron L, Bellavance A, Marchand L. Neuropathy and mitochondrial myopathy. Ann Neurol 1980; 7: 262-268.
48. Wenning GK, Stefanova N. Recent developments in multiple system atrophy. J Neurol 2009; 256: 1791-808.
49. Sekijima Y, Yoshida K, Tokuda T, et al. Familial transthyretin amyloidosis. In: Pagon RA, Bird TD, Dolan CR, et al. (eds) GeneReviews™. Available via http://www. ncbi. nlm. nih. gov/books/NBK1194/. Accessed 20 Mar 2013.
50. Kenny D, Wetherbee J. Kearns-Sayre syndrome in the elderly: mitochondrial myopathy with advanced heart block. Am Heart J 1990; 120: 440-443.
51. Mashima Y, Kigasawa K, Hasegawa H, Tani M, Oguchi Y. High incidence of pre-excitation syndrome in Japanese families with Leber's hereditary optic neuropathy. Clin Genet 1996; 50: 535-537.
52. Vydt TC, de Coo RF, Soliman OI, et al. Cardiac involvement in adults with m. 3243A & G MELAS gene mutation. Am J Cardiol 2007; 99: 264-269.
53. Morris AAM. Mitochondrial respiratory chain disorders and the liver. Liver 1999; 19: 357-368.
54. Bindoff L. Mitochondrial gastroenterology. In: DiMauro S, Hirano M, Schon EA (eds) Mitochondrial medicine. Informa Healthcare, Boca Raton, FL; 2006: pp. 143-159.
55. Vial G, Dubouchaud H, Leverve XM. Liver mitochondria and insulin resistance. Acta Biochim Pol 2010; 57: 389-392.
56. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5: 233-244.
57. Wong L-J C, Naviaux RK, Brunetti-Pierri, N, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG Mutations. Hum Mutat 2008; 29: E150-172.
58. Schrier SA, Falk MJ. Mitochondrial disorders and the eye. Curr Opin Ophthalmol 2011; 22: 325-331.
59. Fraser JA, Biousse V, Newman NJ. The neuro-ophthalmology of mitochondrial disease. Surv Ophthalmol 2010; 55: 299-334.
60. Kerrison JB, Biousse V, Newman NJ. Retinopathy of NARP syndrome. Arch Ophthalmol 2000; 118: 298-299.
61. Smith PR, Bain SC, Good PA, et al. Pigmentary retinal dystrophy and the syndrome of maternally inherited diabetes and deafness cause by the mitochondrial DNA 3243 tRNA (Leu) A to G mutation. Ophthalmology 1999; 106: 1101-1108.
62. Sitarz KS, Chinnery PF, Yu-Wai-Man P. Disorders of the optic nerve in mitochondrial cytopathies: new ideas on pathogenesis and therapeutic targets. Curr Neurol Neurosci Rep 2012; 12: 308-317.
63. Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988; 242: 1427-1430.
64. Chalmers RM, Schapira AH. Clinical, biochemical and molecular genetic features of Leber's hereditary optic neuropathy. Biochim Biophys Acta 1999; 1410: 147-158.
65. Zeviani M. OPA1 mutations and mitochondrial DNA damage: keeping the magic circle in shape. Brain 2008; 131: 314-317.
66. Leonard JV, Schapira AH. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet 2000; 335: 299-304.
67. McFarland R, Taylor RW, Chinnery PF et al. A novel sporadic mutation in cytochrome c oxidase subunit II as a cause of rhabdomyolysis. Neuromuscul Disord 2004; 14: 162-166.
68. Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008; 83: 254-260.
69. Fischel-Ghodsian N. Mitochondrial genetics and hearing loss: the missing link between genotype and phenotype. Proc Soc Exp Biol Med 1998; 218: 1-6.
70. Jacobs HT. Mitochondrial deafness. Ann Med 1997; 29: 483-491.
71. Ballana E, Morales E, Rabionet R, et al. Mitochondrial 12S rRNA gene mutations affect RNA secondary structure and lead to variable penetrance in hearing impairment. Biochem Biophys Res Commun 2006; 341: 950-957.
72. Guan MX, Yan Q, Li X, et al. Mutation in TRMU related to transfer RNA modification modulates the phenotypic expression of the deafness-associated mitochondrial 12S ribosomal RNA mutations. Am J Hum Genet 2006; 79: 291-302.
73. Niaudet P. Mitochondrial disorders and the kidney. Arch Dis Child 1998; 78: 387-390.
74. Niaudet P, Rotig A. The kidney in mitochondrial cytopathies. Kidney Int 1997; 51: 1000-1007.
75. Guéry B, Choukroun G, Noël LH, et al. The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. J Am Soc Nephrol 2003; 14: 2099-2108.
76. Doleris LM, Hill GS, Chedin P, et al. Focal segmental glomerulosclerosis associated with mitochondrial cytopathy. Kidney Int 2000; 58: 1851-1858.
77. Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 1962; 41: 1776-1804.
78. Odawara M. Involvement of mitochondrial gene abnormalities in the pathogenesis of diabetes mellitus. Ann NY Acad Sci 1996; 786: 72-81.
79. Gerbitz KD, van den Ouweland JM, Maassen JA, Jaksch M. Mitochondrial diabetes mellitus: a review. Biochim Biophys Acta 1995; 1271: 253-260.
80. van den Ouweland JM, Lemkes HH, et al. Maternally inherited diabetes and deafness is a distinct subtype of diabetes and associates with a single point mutation in the mitochondrial tRNA (Leu(URR)) gene. Diabetes 1994; 43: 746-751.
81. Anon. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 34-1987. A 30-year-old woman with an ocular motility disturbance, myopathy, and hypocalcemia. N Engl J Med 1987; 317: 493-501.
82. Yang CY, Lam HC, Lee HC, et al. MELAS syndrome associated with diabetes mellitus and hyperthyroidism: a case report from Taiwan. Clin Endocrinol 1995; 43: 235-239.
83. Finsterer J, Jarius C, Eichberger H. Phenotype variability in 130 adult patients with respiratory chain disorders. J Inherit Metab Dis 2001; 24: 560-576.
84. Quade A, Zierz S, Klingmüller D. Endocrine abnormalities in mitochondrial myopathy with external ophthalmoplegia. Clin Invest 1992; 70: 396-402.
85. Chen CM, Huang CC. Gonadal dysfunction in mitochondrial encephalomyopathies. Eur Neurol 1995; 35: 281-286.
86. Harvey JN, Barnett D. Endocrine dysfunction in Kearns-Sayre syndrome. Clin Endocrinol 1992; 37: 97-103.
87. Matsuzaki M, Izumi T, Shishikura K, Suzuki H, Hirayama Y. Hypothalamic growth hormone deficiency and supplementary GH therapy in two patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes. Neuropediatrics 2002; 33: 271-273.
88. Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology 1995; 32: 132-138.
89. Kuratsune H, Yamaguti K, Takahashi M, Tagawa S, Kitani T. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis 1994; 18(Suppl. 1): 62-67.
90. Griggs RC, Karpati G. Muscle pain, fatigue, and mitochondriopathies. N Engl J Med 1999; 341: 1077-1078.
91. Smits B, van den Heuvel L, Knoop H, Küsters B, Janssen A, Borm G, et al. Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome. Mitochondrion 2011; 11: 735-738.